Intellectual Property and Public Health: copying of HIV/Aids drugs by Brazilian public and private pharmaceutical laboratories - HAL Accéder directement au contenu
Article dans une revue RECIIS – Revista Eletrônica de Comunicação, Informação & Inovação em Saúde Année : 2007

Intellectual Property and Public Health: copying of HIV/Aids drugs by Brazilian public and private pharmaceutical laboratories

Résumé

Brazilian public and private laboratories' experience in copying ARVs since 1993 has been a technological learning process that in some cases has produced innovations. Reproducing drugs and synthesizing their active principles involves the combination of information available in patent documents and the partial rediscovery of certain know-how through laboratory manipulations. Chemists have to reconstruct the numerous "cat leaps" in patent documents, and in so doing often improve on the published processes or formulae. Generics laboratories are also able to use this knowledge base to invent new formulae, combinations of existing molecules, or to discover new molecules. Since 2000 the five laboratories studied have filed about ten patents on ARVs. We pieced together this technological learning process by interviewing chemists at generics laboratories, using the methods of the sociology of science.

Domaines

Sociologie
Fichier principal
Vignette du fichier
RECIIS.pdf ( 266.71 Ko ) Télécharger
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

halshs-01894146, version 1 (23-12-2018)

Identifiants

Citer

Maurice Cassier, Marilena Correa. Intellectual Property and Public Health: copying of HIV/Aids drugs by Brazilian public and private pharmaceutical laboratories. RECIIS – Revista Eletrônica de Comunicação, Informação & Inovação em Saúde, 2007, 1 (1), pp.83-90. ⟨10.3395/reciis.v1i1.38en⟩. ⟨halshs-01894146⟩
164 Consultations
378 Téléchargements
Dernière date de mise à jour le 21/04/2024
comment ces indicateurs sont-ils produits

Altmetric

Partager

Gmail Facebook Twitter LinkedIn Plus